Hot Undervalued Stocks To Own Right Now

tags:MMI,ZAGG,PANW,GNFTF,LOOK,CGI,

Using Money Morning's proprietary VQScore stock valuation system, I found an undervalued dividend stock that's flashing a huge "Buy" signal right now.

Through the system, we track the 1,500 most profitable companies on the market. A VQScore of 4.00 or higher puts a stock in the "Buy Zone." These are the stocks priced to make you money.

And this stock is a screaming buy, with a top score of 4.75….

It's undervalued right now because Wall Street is ignoring huge revenue growth potential thanks to international expansion.

Hot Undervalued Stocks To Own Right Now: Marcus & Millichap, Inc.(MMI)

Advisors' Opinion:

• [By Motley Fool Transcribers]

  Marcus & Millichap Inc  (NYSE:MMI)Q4 2018 Earnings Conference CallFeb. 20, 2019, 5:00 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Shane Hupp]

  Marcus & Millichap (NYSE:MMI) was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat reports.

• [By Logan Wallace]

  Marcus & Millichap Inc (NYSE:MMI) major shareholder Phoenix Investments Holdings L sold 3,000 shares of Marcus & Millichap stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $40.27, for a total transaction of $120,810.00. Following the completion of the transaction, the insider now directly owns 16,532,215 shares in the company, valued at approximately $665,752,298.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Hot Undervalued Stocks To Own Right Now: ZAGG Inc(ZAGG)

Advisors' Opinion:

• [By Timothy Green]

  Shares of ZAGG Inc. (NASDAQ:ZAGG) soared on Wednesday after the mobile device accessory company reported first-quarter results. ZAGG handily beat analyst expectations on all fronts, registering an unexpected double-digit increase in revenue. As of 12:45 p.m. EDT, the stock was up about 26%.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on ZAGG (ZAGG)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin]

  Shares of ZAGG Inc (NASDAQ: ZAGG) got a boost, shooting up 34 percent to $15.3628 after the company posted better-than-expected Q1 earnings.

  Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares were also up, gaining 9 percent to $8.125 after reporting Q1 results.

Hot Undervalued Stocks To Own Right Now: Palo Alto Networks, Inc.(PANW)

Advisors' Opinion:

• [By ]

  Palo Alto Networks (NYSE: PANW) shares jumped 7% after hours yesterday when the company topped earnings expectations and issued strong guidance.

  We've maintained a PANW in the portfolio since June — and we suggested adding to your position back on Feb. 14th after the stock tagged our preliminary target of $160. Now that the stock is approaching $180 after hours, it has the momentum it needs to make a run at its 2015 all-time highs near $200.

• [By Motley Fool Transcription]

  Palo Alto Networks, Inc. (NYSE:PANW) Q4 2018 Earnings Conference Call September 6, 2018, 4:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Palo Alto Networks (PANW)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Harsh Chauhan]

  Over a year ago, cybersecurity specialists Palo Alto Networks (NYSE:PANW) and FireEye (NASDAQ:FEYE) were trying to turn investor sentiment in their favor. While Palo Alto was facing execution challenges thanks to an outdated sales model, FireEye was struggling thanks to executive turnover and inconsistent financial performance.

• [By Nicholas Rossolillo]

  During the first quarter of 2018, Check Point's revenue only rose 4% year over year. Meanwhile, younger competitor Palo Alto Networks (NYSE:PANW) has been growing sales by double digits with aggressive marketing and newer technology.

Hot Undervalued Stocks To Own Right Now: Genfit SA (GNFTF)

Advisors' Opinion:

• [By ]

  With one product candidate at phase 3 of development, Genfit (OTCPK:GNFTF) should interest institutional investors quite a bit. The results are expected by the end of 2019, which the market should remember well. Keep in mind that beneficial results could make the share price increase quite a bit. Having mentioned this, the company may need more financing to finish other product candidates still at phase 2 of development. Investors should remember that further sale of equity to finance these trials could lead to share price depreciation in the near future.

• [By Keith Speights]

  French drugmaker Genfit (NASDAQOTH:GNFTF) expects to report interim results from a phase 3 study of elafibranor in treating NASH later in 2019. The company could be set to file for regulatory approval in the NASH indication by late 2020 or early 2021. Elafibranor could potentially be viewed as more effective and safer than Ocaliva based on earlier clinical results. Genfit is also evaluating elafibranor in treating PBC, with positive phase 2 results announced in December 2018.

• [By ]

  Here's what we wrote: "With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The company's programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the "sweet spot" of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space."

• [By ]

  This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That's why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.

Hot Undervalued Stocks To Own Right Now: LookSmart Ltd.(LOOK)

Advisors' Opinion:

• [By Stephan Byrd]

  Lookers (LON:LOOK)‘s stock had its “buy” rating restated by investment analysts at Peel Hunt in a note issued to investors on Friday.

• [By Shane Hupp]

  Peel Hunt reissued their buy rating on shares of Lookers (LON:LOOK) in a research note issued to investors on Wednesday morning.

  A number of other equities analysts also recently weighed in on the stock. Numis Securities reaffirmed a buy rating and issued a GBX 130 ($1.76) price target on shares of Lookers in a research note on Wednesday, March 7th. JPMorgan Chase upped their price target on shares of Lookers from GBX 109 ($1.48) to GBX 130 ($1.76) and gave the stock an overweight rating in a research note on Thursday, March 8th. Liberum Capital reaffirmed a buy rating and issued a GBX 145 ($1.97) price target on shares of Lookers in a research note on Wednesday, March 7th. Finally, Canaccord Genuity reaffirmed a buy rating and issued a GBX 146 ($1.98) price target on shares of Lookers in a research note on Monday, March 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Lookers has an average rating of Buy and an average price target of GBX 137.71 ($1.87).

Hot Undervalued Stocks To Own Right Now: Celadon Group, Inc.(CGI)

Advisors' Opinion:

• [By Ethan Ryder]

  Scopus Asset Management L.P. reduced its holdings in shares of Celadon Group, Inc. (NYSE:CGI) by 57.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 900,000 shares of the transportation company’s stock after selling 1,218,285 shares during the quarter. Scopus Asset Management L.P. owned approximately 3.18% of Celadon Group worth $3,330,000 as of its most recent filing with the SEC.

• [By Stephan Byrd]

  Russell Investments Group Ltd. boosted its position in shares of Celadon Group, Inc. (NYSE:CGI) by 26.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,347,089 shares of the transportation company’s stock after purchasing an additional 283,476 shares during the quarter. Russell Investments Group Ltd. owned about 4.76% of Celadon Group worth $4,983,000 as of its most recent filing with the Securities and Exchange Commission.